Core Viewpoint - Sana Biotechnology (SANA) has shown a significant price increase of 10.4% over the past four weeks, with a mean price target of $8.71 indicating a potential upside of 74.2% from its current price of $5 [1]. Price Targets - The average price target consists of seven estimates ranging from a low of $6.00 to a high of $12.00, with a standard deviation of $2.43, suggesting a variability in analyst estimates [2]. - The lowest estimate indicates a 20% increase from the current price, while the highest suggests a 140% upside potential [2]. Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about SANA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 0.6% increase over the last 30 days [4][12]. - The Zacks Consensus Estimate for the current year has improved, with one estimate moving higher and no negative revisions [12]. - SANA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are often sought after by investors, their reliability has been questioned, as they can mislead rather than guide investment decisions [3][7]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9].

Core Viewpoint - Penske Automotive Group, Inc. is a significant entity in the international transportation services sector, focusing on automotive and commercial truck retailing [1] Group 1: Stock Performance - Barclays has set a price target of $190 for PAG, indicating a potential increase of approximately 16.55% from the current trading price of $163.02 [2] - The stock's current price reflects a slight decrease of $0.94, or about -0.57%, with trading occurring between $161.19 and $163.225 today [2] - Over the past year, the stock has experienced a high of $189.51 and a low of $134.05, showcasing its volatility and growth potential [2] Group 2: Market Capitalization and Trading Activity - Penske Automotive Group's market capitalization is approximately $10.74 billion, indicating its substantial market presence [3] - Today's trading volume is 167,675 shares on the NYSE, reflecting active investor interest and potential influence on stock price movements [3] Group 3: Upcoming Financial Results - The company is scheduled to release its financial results for the fourth quarter and full year of 2025 on February 11, 2026, which could significantly impact stock performance [4] - Investors are expected to closely analyze the financial results to gauge the company's operational efficiency and market strategy, essential for meeting Barclays' price target [4]

Group 1 - Roblox (RBLX) closed at $84.65, with a 0.9% gain over the past four weeks, and analysts set a mean price target of $132, indicating a 55.9% upside potential [1] - The mean estimate consists of 26 short-term price targets with a standard deviation of $34.29, where the lowest estimate is $65.00 (23.2% decline) and the highest is $180.00 (112.6% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 2% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RBLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting gains, they can indicate the direction of price movement, serving as a useful guide [14]

Core Viewpoint - Assertio (ASRT) shows significant upside potential with a mean price target of $38.94, indicating a 249.9% increase from its current price of $11.13 [1] Price Targets and Analyst Consensus - The average price target consists of five estimates ranging from a low of $24.74 to a high of $45.00, with a standard deviation of $9.04, suggesting a high degree of variability among analysts [2] - The lowest estimate indicates a potential increase of 122.3%, while the most optimistic estimate suggests a 304.3% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ASRT's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 6.6%, with one estimate moving higher and no negative revisions [12] - ASRT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3][7] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism, as they may not reliably indicate actual stock price movements [10]

Core Viewpoint - KalVista Pharmaceuticals, Inc. (KALV) shows significant upside potential with a mean price target of $33.22, indicating an 118% increase from the current trading price of $15.24 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $5.52, suggesting variability in analyst predictions [2] - The lowest price target is $22.00, indicating a 44.4% increase, while the highest target is $39.00, suggesting a potential surge of 155.9% [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about KALV's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 10.6% over the past month, with no negative revisions [12] - KALV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Immunovant, Inc. (IMVT) shows potential for significant upside, with a mean price target of $40.31 indicating a 47.4% increase from its current price of $27.35 [1] Price Targets and Analyst Consensus - The average price target consists of 16 estimates ranging from a low of $16.00 to a high of $57.00, with a standard deviation of $13.5, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 41.5%, while the highest indicates an upside of 108.4% [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price direction, which can be a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about IMVT's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - Over the last 30 days, two earnings estimates have been revised upward, leading to a 1% increase in the Zacks Consensus Estimate [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Verrica Pharmaceuticals Inc. (VRCA) shows significant upside potential with a mean price target of $15.67, indicating a 97.1% increase from the current trading price of $7.95 [1]. Price Targets - The average price target consists of three estimates ranging from a low of $10.00 to a high of $20.00, with a standard deviation of $5.13, suggesting a variability in analyst predictions [2]. - The lowest estimate indicates a 25.8% increase, while the highest suggests a 151.6% upside [2]. Analyst Sentiment - There is strong agreement among analysts regarding VRCA's ability to exceed previous earnings estimates, which supports the potential for stock price appreciation [4][11]. - The Zacks Consensus Estimate for the current year has increased by 12.9% due to positive revisions in earnings estimates [12]. Zacks Rank - VRCA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. Caution on Price Targets - While price targets are a common metric, they should be approached with skepticism as they may not accurately predict stock price movements [3][10]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8].

Core Viewpoint - Sunrun (RUN) shares have seen a 0.9% increase over the past four weeks, closing at $18.09, with a mean price target of $23.21 indicating a potential upside of 28.3% according to Wall Street analysts [1] Price Targets - The average of 19 short-term price targets ranges from a low of $19.00 to a high of $30.00, with a standard deviation of $2.78, suggesting a potential increase of 5% to 65.8% from the current price [2] - A low standard deviation indicates a greater agreement among analysts regarding the price estimates, which can be a useful metric for investors [2][9] Analyst Sentiment - Analysts have shown increasing optimism about Sunrun's earnings prospects, with a strong consensus on revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, one estimate has increased while there have been no negative revisions, leading to a 26.8% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - Sunrun currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as analysts may set overly optimistic targets due to business incentives [3][8][10]

Group 1 - HUTCHMED (HCM) closed at $13.75, with a 0.2% gain over the past four weeks, and analysts set a mean price target of $21.44, indicating a 55.9% upside potential [1] - The average price targets range from a low of $13.75 to a high of $32.00, with a standard deviation of $7.81, suggesting variability in analyst estimates [2] - Analysts have shown increasing optimism regarding HCM's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for HCM has increased by 14.6% over the past month, indicating positive sentiment among analysts [12] - HCM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be positive for HCM [14]

Group 1 - The stock of Global-e Online Ltd. (GLBE) closed at $38.4, reflecting a 0.5% gain over the past four weeks, with a mean price target of $48.85 indicating a potential upside of 27.2% [1] - Analysts have set 13 short-term price targets for GLBE, ranging from a low of $41.00 to a high of $64.00, with a standard deviation of $5.58, suggesting a variability in estimates [2] - There is strong agreement among analysts regarding GLBE's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for GLBE has increased by 2.2% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - GLBE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]